首页> 外文期刊>European journal of cardio-thoracic surgery: Official journal of the European Association for Cardio-thoracic Surgery >BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough anti-apoptotic mechanism in rat hearts.
【24h】

BH4 peptide derivative from Bcl-xL attenuates ischemia/reperfusion injury thorough anti-apoptotic mechanism in rat hearts.

机译:Bcl-xL的BH4肽衍生物可通过抗凋亡机制减轻大鼠心脏的缺血/再灌注损伤。

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To prevent apoptosis is thought to be promising for myocardial protection in cardiac surgery. Recently, we showed that BH4 domain of Bcl-xL is essential for the prevention of apoptosis, and that BH4 fused to HIV TAT protein (TAT-BH4) prevented apoptotic cell death. Then, we hypothesized TAT-BH4 may attenuate ischemia/reperfusion injury in rat hearts. Methods: The isolated rat hearts in the TAT-BH4 preconditioning group (BH4 group, n=8) or control group (C group, n=8) were subjected to warm ischemia (37 degrees C) for 30min followed by 60min of reperfusion using Langendorff perfusion system. Results: Left ventricular developed pressure and maximum dP/dt after reperfusion were significantly improved in the BH4 group than those in the C group (P<0.01). Recovery of mitochondrial respiration was significantly better in the BH4 group (P<0.05). Moreover, expression of caspase-3 and TUNEL-positive myocardium were decreased in the BH4 group than those in the C group. Conclusions: These results demonstrated that TAT-BH4 attenuates myocardial ischemia/reperfusion injury through preventing myocardial apoptosis. Thus, TAT-BH4 may be a novel therapeutic agent for myocardial protection in cardiac surgery.
机译:目的:预防细胞凋亡被认为对心脏外科手术的心肌保护有希望。最近,我们显示Bcl-xL的BH4结构域对于预防细胞凋亡至关重要,并且与HIV TAT蛋白(TAT-BH4)融合的BH4可以防止凋亡。然后,我们假设TAT-BH4可以减轻大鼠心脏的缺血/再灌注损伤。方法:将TAT-BH4预处理组(BH4组,n = 8)或对照组(C组,n = 8)中的离体大鼠心脏进行37分钟的热缺血(30°C),然后再进行60min的再灌注Langendorff灌注系统。结果:BH4组的左心室发育压力和最大dP / dt比C组显着改善(P <0.01)。 BH4组线粒体呼吸的恢复明显更好(P <0.05)。而且,BH4组的Caspase-3和TUNEL阳性心肌的表达均低于C组。结论:这些结果表明,TAT-BH4可通过预防心肌细胞凋亡来减轻心肌缺血/再灌注损伤。因此,TAT-BH4可能是用于心脏手术中的心肌保护的新型治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号